Ra Capital Management as of Dec. 31, 2014
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 48 positions in its portfolio as reported in the December 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Achillion Pharmaceuticals | 12.1 | $113M | 9.2M | 12.25 | |
| Sangamo Biosciences (SGMO) | 11.8 | $110M | 7.2M | 15.21 | |
| BioCryst Pharmaceuticals (BCRX) | 9.2 | $86M | 7.1M | 12.16 | |
| Regulus Therapeutics | 8.2 | $76M | 4.7M | 16.04 | |
| Dyax | 7.5 | $70M | 4.9M | 14.06 | |
| Tg Therapeutics (TGTX) | 5.7 | $53M | 3.4M | 15.84 | |
| Bluebird Bio (BLUE) | 5.0 | $46M | 506k | 91.72 | |
| Dicerna Pharmaceuticals | 4.3 | $40M | 2.4M | 16.47 | |
| ACADIA Pharmaceuticals (ACAD) | 3.5 | $33M | 1.0M | 31.76 | |
| Coherus Biosciences (CHRS) | 2.7 | $25M | 1.6M | 16.32 | |
| Zs Pharma | 2.5 | $24M | 565k | 41.57 | |
| Zafgen | 2.4 | $23M | 733k | 30.84 | |
| Xencor (XNCR) | 2.4 | $22M | 1.4M | 16.04 | |
| Forward Pharma A/s | 2.2 | $20M | 971k | 20.83 | |
| Novavax | 2.1 | $19M | 3.2M | 5.93 | |
| Trevena | 1.9 | $18M | 3.0M | 5.98 | |
| Juno Therapeutics | 1.6 | $15M | 280k | 52.22 | |
| Therapeuticsmd | 1.5 | $14M | 3.2M | 4.45 | |
| Ophthotech | 1.5 | $14M | 311k | 44.87 | |
| Proteon Therapeutics | 1.4 | $13M | 1.3M | 10.40 | |
| Tenax Therapeutics | 1.1 | $10M | 2.7M | 3.84 | |
| Bellicum Pharma | 1.0 | $9.3M | 1.0M | 9.10 | |
| Aurinia Pharmaceuticals (AUPH) | 1.0 | $9.0M | 2.5M | 3.64 | |
| Scynexis | 0.9 | $8.4M | 840k | 9.98 | |
| Rockwell Medical Technologies | 0.8 | $7.3M | 706k | 10.28 | |
| Akebia Therapeutics (AKBA) | 0.8 | $7.0M | 597k | 11.64 | |
| Vical Incorporated | 0.7 | $6.5M | 6.2M | 1.05 | |
| Cti Biopharma | 0.6 | $5.9M | 2.5M | 2.36 | |
| Versartis | 0.6 | $5.2M | 231k | 22.45 | |
| Auris Med Hldg | 0.4 | $3.7M | 940k | 3.90 | |
| Biota Pharmaceuticals | 0.3 | $3.1M | 1.4M | 2.24 | |
| Ocera Therapeutics | 0.3 | $2.7M | 418k | 6.37 | |
| T2 Biosystems | 0.3 | $2.7M | 138k | 19.24 | |
| Agios Pharmaceuticals (AGIO) | 0.2 | $2.0M | 18k | 112.05 | |
| Wafergen Bio-systems | 0.2 | $1.7M | 560k | 3.00 | |
| Merrimack Pharmaceuticals In | 0.1 | $1.3M | 116k | 11.30 | |
| Ptc Therapeutics I (PTCT) | 0.1 | $1.3M | 26k | 51.78 | |
| Newlink Genetics Corporation | 0.1 | $1.2M | 30k | 39.77 | |
| Alkermes (ALKS) | 0.1 | $1.1M | 19k | 58.54 | |
| Regeneron Pharmaceuticals (REGN) | 0.1 | $1.0M | 2.5k | 410.20 | |
| Amgen (AMGN) | 0.1 | $940k | 5.9k | 159.32 | |
| Celgene Corporation | 0.1 | $973k | 8.7k | 111.84 | |
| Repligen Corporation (RGEN) | 0.1 | $891k | 45k | 19.80 | |
| Keryx Biopharmaceuticals | 0.1 | $838k | 59k | 14.16 | |
| Biogen Idec (BIIB) | 0.1 | $883k | 2.6k | 339.62 | |
| Celladon | 0.1 | $799k | 41k | 19.54 | |
| Kythera Biopharmaceuticals I | 0.1 | $789k | 23k | 34.68 | |
| Puma Biotechnology (PBYI) | 0.1 | $587k | 3.1k | 189.35 |
